Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 6Sarcoma 5Liposarcoma 4Leiomyosarcoma 3Neoplasms 2Fallopian Tube Neoplasms 2Sarcoma, Ewing 1Recurrent High Grade Meningioma 1Recurrence 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm Metastasis 1Liposarcoma, Myxoid 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Gemcitabine 57Paclitaxel 50Cyclophosphamide 45pembrolizumab 44Carboplatin 41Bevacizumab 38Cisplatin 33Docetaxel 31Fluorouracil 30Nivolumab 29Capecitabine 29Pemetrexed 24Irinotecan 24Oxaliplatin 23Dexamethasone 23Ipilimumab 22Leucovorin 21Radiotherapy 20Sorafenib 19Doxorubicin 19Everolimus 18Cetuximab 18fludarabine 17Albumin-Bound Paclitaxel 17trametinib 15Sunitinib 15Rituximab 15Erlotinib Hydrochloride 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasms × Trabectedin × Clear all
NCT00060944 2014-09-08

A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
271 enrolled 13 charts
Sarcoma

Leiomyosarcoma, Liposarcoma, Neoplasm Metastasis, Neoplasms

NCT00786838 2014-04-11

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Completed
76 enrolled 17 charts
BreastGynecologicSarcoma

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡